OBJECTIVE: To determine the pharmacokinetics of meloxicam after IV and PO administration to 6 healthy sheep. ANIMALS: 6 healthy adult Dorset cross sheep (5 males and 1 female). PROCEDURES: Meloxicam (0.5 mg/kg, IV, or 1.0 mg/kg, PO) was administered in a randomized crossover design with a 10-day washout period. Blood samples were collected at predetermined times over 96 hours. Serum drug concentrations were determined by high-pressure liquid chromatography with mass spectrometry. Computer software was used to estimate values of pharmacokinetic parameters through noncompartmental methods. RESULTS: Following IV administration (n = 5), the geometric mean (range) elimination half-life was 14.0 hours (10.5 to 17.0 hours), volume of distribution was 0.204 L/kg (0.171 to 0.272 L/kg), and clearance was 0.17 mL/min/kg (0.12 to 0.27 mL/min/kg). Following oral administration (n = 6), maximum serum concentration was 1.72 μg/mL (1.45 to 1.93 μg/mL), time to maximum serum concentration was 19.0 hours (12.0 to 24.0 hours), clearance per bioavailability was 0.22 mL/min/kg (0.16 to 0.30 mL/min/kg), and terminal half-life was 15.4 hours (13.2 to 17.7 hours). Bioavailability of orally administered meloxicam was calculated as 72% (40% to 125%; n = 5). No adverse effects were evident following meloxicam administration via either route. CONCLUSIONS AND CLINICAL RELEVANCE: Meloxicam administered PO at 1.0 mg/kg has good bioavailability with slow elimination kinetics in sheep. These data suggested that meloxicam may be clinically useful, provided the safety and analgesic efficacy of meloxicam as well as feed-related influences on its pharmacokinetics are established in ruminants.
OBJECTIVE: To determine the pharmacokinetics of meloxicam after IV and PO administration to 6 healthy sheep. ANIMALS: 6 healthy adult Dorset cross sheep (5 males and 1 female). PROCEDURES: Meloxicam (0.5 mg/kg, IV, or 1.0 mg/kg, PO) was administered in a randomized crossover design with a 10-day washout period. Blood samples were collected at predetermined times over 96 hours. Serum drug concentrations were determined by high-pressure liquid chromatography with mass spectrometry. Computer software was used to estimate values of pharmacokinetic parameters through noncompartmental methods. RESULTS: Following IV administration (n = 5), the geometric mean (range) elimination half-life was 14.0 hours (10.5 to 17.0 hours), volume of distribution was 0.204 L/kg (0.171 to 0.272 L/kg), and clearance was 0.17 mL/min/kg (0.12 to 0.27 mL/min/kg). Following oral administration (n = 6), maximum serum concentration was 1.72 μg/mL (1.45 to 1.93 μg/mL), time to maximum serum concentration was 19.0 hours (12.0 to 24.0 hours), clearance per bioavailability was 0.22 mL/min/kg (0.16 to 0.30 mL/min/kg), and terminal half-life was 15.4 hours (13.2 to 17.7 hours). Bioavailability of orally administered meloxicam was calculated as 72% (40% to 125%; n = 5). No adverse effects were evident following meloxicam administration via either route. CONCLUSIONS AND CLINICAL RELEVANCE: Meloxicam administered PO at 1.0 mg/kg has good bioavailability with slow elimination kinetics in sheep. These data suggested that meloxicam may be clinically useful, provided the safety and analgesic efficacy of meloxicam as well as feed-related influences on its pharmacokinetics are established in ruminants.
Authors: Misha L Dunbar; Krista J Walkowiak; Jill Schappa Faustich; Aaron K Rendahl; Melanie L Graham Journal: J Am Assoc Lab Anim Sci Date: 2019-03-07 Impact factor: 1.232
Authors: Katie E Olagaray; Barry J Bradford; Lorraine M Sordillo; Jeffery C Gandy; Laman K Mamedova; Turner H Swartz; Trey D Jackson; Emma K Persoon; Caitlin S Shugart; Curtis R Youngs Journal: J Anim Sci Biotechnol Date: 2020-07-01
Authors: Daniela M Meléndez; Sonia Marti; Edmond A Pajor; Pritam K Sidhu; Désirée Gellatly; Eugene D Janzen; Timothy D Schwinghamer; Johann F Coetzee; Karen S Schwartzkopf-Genswein Journal: PLoS One Date: 2019-05-24 Impact factor: 3.240
Authors: Alyssa N Woodland; Dominique Van der Saag; Benjamin Kimble; Peter J White; Merran Govendir; Sabrina Lomax Journal: PLoS One Date: 2019-04-24 Impact factor: 3.240